{"answer":{"query":"orencia","resolved_as":"name","packages":6,"applications":["BLA125118"],"identity":{"application_numbers":["BLA125118"],"marketing_categories":["BLA"],"labelers":[{"text":"E.R. SQUIBB & SONS, LLC.","untrusted":true}],"dosage_forms":[{"text":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","untrusted":true},{"text":"INJECTION, SOLUTION","untrusted":true}],"marketing_start":{"earliest":"2009-01-01","latest":"2017-03-30","packages_with_a_start_date":5}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":6,"negotiated_price_ends":null,"rows":[{"ndc":"00003218710","name":{"text":"ORENCIA","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00003218713","name":{"text":"ORENCIA","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00003218811","name":{"text":"Orencia SC","untrusted":true},"class":"B","nadac_per_unit":1468.33141,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00003218851","name":{"text":"Orencia SC","untrusted":true},"class":"B","nadac_per_unit":1470.99464,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00003281411","name":{"text":"ORENCIA SC","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00003281811","name":{"text":"ORENCIA SC","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":null},"label_history":{"events_total":23,"non_cmc_events":22,"counts_by_class":{"LABELING":12,"EFFICACY":10},"cmc_events":1,"recent_non_cmc_events":[{"application":"BLA125118","submission_no":255,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-05-29","documents":[{"type":"Letter","date":"2024-05-30","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/125118Orig1s255ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-05-31","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125118s255lbl.pdf","untrusted":true}}],"fact_id":"639ab1db30cee99a9e6dd2af"},{"application":"BLA125118","submission_no":249,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-01-19","documents":[{"type":"Letter","date":"2024-01-23","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/125118Orig1s249ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-01-23","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125118s249lbl.pdf","untrusted":true}}],"fact_id":"b737eb739aa1e34ccb5be378"},{"application":"BLA125118","submission_no":250,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2023-10-30","documents":[{"type":"Label","date":"2023-10-31","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125118s250lbl.pdf","untrusted":true}},{"type":"Letter","date":"2023-10-31","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/125118Orig1s250ltr.pdf","untrusted":true}}],"fact_id":"bc1c2a1e81600317f15c6ea6"},{"application":"BLA125118","submission_no":235,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-04-13","documents":[{"type":"Letter","date":"2022-04-15","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125118Orig1s235ltr.pdf","untrusted":true}}],"fact_id":"4b870608e89673d9cbea28e5"},{"application":"BLA125118","submission_no":240,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2021-12-15","documents":[{"type":"Label","date":"2021-12-15","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125118s240lbl.pdf","untrusted":true}},{"type":"Letter","date":"2021-12-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/125118Orig1s240ltr.pdf","untrusted":true}}],"fact_id":"a9c4f906e42caa45e6ffac6a"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":1,"te_code_counts":{"NOT_PROVIDED":1},"marketing_status_counts":{"Prescription":1},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"BLA125118","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"ORENCIA","untrusted":true},"form":{"text":"INJECTABLE; IV (INFUSION)","untrusted":true},"strength":{"text":"250MG","untrusted":true}}]},"supply":{"fda_shortage_status_counts":{},"packages_with_a_termination_date":1,"next_package_termination_dates":[],"packages_with_future_termination_date":0,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"ABATACEPT","untrusted":true},"recruiting_interventional_count":33,"not_yet_recruiting_count":1,"by_phase":{"EARLY_PHASE1":1,"PHASE1/PHASE2":6,"PHASE1":3,"PHASE2":12,"PHASE3":7,"PHASE4":2,"PHASE2/PHASE3":2},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT06731504","title":{"text":"HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT","untrusted":true},"phase":["EARLY_PHASE1"],"sponsor":{"text":"Duke University","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2025-11-12","link":{"text":"https://clinicaltrials.gov/study/NCT06731504","untrusted":true}},{"nct_id":"NCT07675174","title":{"text":"PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Northwell Health","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2026-08-14","link":{"text":"https://clinicaltrials.gov/study/NCT07675174","untrusted":true}},{"nct_id":"NCT06055608","title":{"text":"Advancing Transplantation Outcomes in Children","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"National Institute of Allergy and Infectious Diseases (NIAID)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-23","start_date":"2024-05-22","link":{"text":"https://clinicaltrials.gov/study/NCT06055608","untrusted":true}},{"nct_id":"NCT06918990","title":{"text":"Treatment of Antibody-Mediated Rejection (ABMR) With CarBel","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"National Institute of Allergy and Infectious Diseases (NIAID)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-23","start_date":"2026-05-27","link":{"text":"https://clinicaltrials.gov/study/NCT06918990","untrusted":true}},{"nct_id":"NCT06654882","title":{"text":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Duke University","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-21","start_date":"2026-01-09","link":{"text":"https://clinicaltrials.gov/study/NCT06654882","untrusted":true}}],"fact_id":"240ee3234816564fdd5c8946"}]},"spending":{"reported_under":{"generic":{"text":"Abatacept","untrusted":true},"brand":{"text":"Orencia","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":172167789.03,"claims":31561,"beneficiaries":4438,"average_spending_per_claim_usd":5455.0802899,"fact_id":"c95a3dad1a9d044d6af00057"},{"year":2021,"gross_spending_usd":168467142.93,"claims":29820,"beneficiaries":4269,"average_spending_per_claim_usd":5649.4682404,"fact_id":"496835395462a6da1195afe4"},{"year":2022,"gross_spending_usd":170833810.16,"claims":29460,"beneficiaries":4109,"average_spending_per_claim_usd":5798.8394487,"fact_id":"8e86a13bb7ae5cca3aa419cc"},{"year":2023,"gross_spending_usd":178400674.89,"claims":29171,"beneficiaries":4032,"average_spending_per_claim_usd":6115.6859515,"fact_id":"5eb48f1997d11fe7eb6308d0"},{"year":2024,"gross_spending_usd":183919526.08,"claims":30087,"beneficiaries":4112,"average_spending_per_claim_usd":6112.9233915,"fact_id":"b41816f7880aee8fc1185d0a"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"biologic_status":{"products":[{"application":"BLA125118","status":"Reference","name":{"text":"Orencia","untrusted":true},"proper_name":{"text":"abatacept","untrusted":true},"license_status":"Licensed","approval_date":"2005-12-23","reference_product":null,"interchangeable_date":null,"biosimilars_listed":0,"interchangeables_listed":0,"biosimilars":[],"interchangeables":[],"purple_book_version":"purplebook-2026-10","read_on":"2026-11-07T07:33:31.186Z","fact_id":"ca18afa6139dbcb5379accb9"}],"reading":"what the FDA Purple Book lists on its read date, a record and not a forecast of launch or substitution"},"payment_limit":{"codes":[{"hcpcs":"J0129","quarter":"2026Q4","effective":"October 1, 2026 through December 31, 2026","payment_limit_usd":45.937,"dosage_descriptor":{"text":"10 MG","untrusted":true},"packages_matched":5,"read_on":"2026-11-07T07:31:28.000Z","source_url":{"text":"https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files","untrusted":true},"fact_id":"c02b84ace98cd9ef34ba4dcc"}],"codes_total":1,"meaning":"a Medicare Part B payment ceiling for providers billing a HCPCS code, per dosage descriptor unit; not a price a patient pays, and the presence of a code does not indicate that Medicare covers a product"},"orphan_designation":{"ingredients":[{"ingredient":{"text":"Abatacept; abatacept","untrusted":true},"designation_count":4,"approved_count":1,"recent":[{"designated":"2017-12-26","use":{"text":"Prevention of graft versus host disease","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Bristol-Myers Squibb Co.","untrusted":true},"approved":true},{"designated":"2017-02-22","use":{"text":"Treatment of giant cell arteritis","untrusted":true},"status":"Designated","sponsor":{"text":"Bristol-Myers Squibb Research & Development","untrusted":true},"approved":false},{"designated":"2017-02-22","use":{"text":"Treatment of idiopathic inflammatory myopathy (IIM)","untrusted":true},"status":"Designated","sponsor":{"text":"Bristol-Myers Squibb Research & Development","untrusted":true},"approved":false},{"designated":"2013-05-30","use":{"text":"Treatment of type 1 diabetes mellitus patients with residual beta cell function","untrusted":true},"status":"Designated","sponsor":{"text":"Orban Biotech LLC","untrusted":true},"approved":false}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"127d42a4bf03c4d2853291e8"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":5,"all_states_medicaid_reimbursed_usd":4541892.67,"all_states_medicaid_paid_prescriptions":1267,"top_states":[{"state":"MN","medicaid_paid_prescriptions":783,"medicaid_reimbursed_usd":2353640.77,"total_reimbursed_usd":2612720.39,"packages":2,"covers":"all_record_types","fact_id":"3d11d003acd0a62dd361cbe4"},{"state":"NV","medicaid_paid_prescriptions":200,"medicaid_reimbursed_usd":999190.77,"total_reimbursed_usd":1009793.99,"packages":1,"covers":"all_record_types","fact_id":"540c6a76bd006c4ff049eda9"},{"state":"UT","medicaid_paid_prescriptions":105,"medicaid_reimbursed_usd":630159.76,"total_reimbursed_usd":643437.94,"packages":1,"covers":"fee_for_service_only","fact_id":"92591658ecfd86a0e424b6ce"},{"state":"KY","medicaid_paid_prescriptions":116,"medicaid_reimbursed_usd":405743.49,"total_reimbursed_usd":405743.49,"packages":1,"covers":"fee_for_service_only","fact_id":"b23c36971ee7cd3f65c70ed1"},{"state":"WV","medicaid_paid_prescriptions":63,"medicaid_reimbursed_usd":153157.88,"total_reimbursed_usd":243814.07,"packages":1,"covers":"all_record_types","fact_id":"ffb2d1e323a964944cfe3056"}],"unlabelled_state_code_xx":null,"built_from_facts":6,"facts_fee_for_service_only":2,"older_year_facts_not_used":116,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"d1a525669103ede0df80a882","field":"ndc.listing","entity":"ndc:00003218713"},{"fact_id":"034731f47f6630bdb85c34f6","field":"ndc.listing","entity":"ndc:00003218811"},{"fact_id":"99af4a7cc396194f11588e2d","field":"ndc.listing","entity":"ndc:00003218851"},{"fact_id":"639ab1db30cee99a9e6dd2af","field":"drug.label_event","entity":"application:BLA125118"},{"fact_id":"b737eb739aa1e34ccb5be378","field":"drug.label_event","entity":"application:BLA125118"},{"fact_id":"bc1c2a1e81600317f15c6ea6","field":"drug.label_event","entity":"application:BLA125118"},{"fact_id":"4b870608e89673d9cbea28e5","field":"drug.label_event","entity":"application:BLA125118"},{"fact_id":"a9c4f906e42caa45e6ffac6a","field":"drug.label_event","entity":"application:BLA125118"},{"fact_id":"1a36eaf8f574d55ac761766c","field":"drug.marketing_status","entity":"application:BLA125118"},{"fact_id":"240ee3234816564fdd5c8946","field":"drug.trial_access","entity":"drug:abatacept"},{"fact_id":"c95a3dad1a9d044d6af00057","field":"drug.partd_spending","entity":"drug:abatacept|orencia"},{"fact_id":"496835395462a6da1195afe4","field":"drug.partd_spending","entity":"drug:abatacept|orencia"},{"fact_id":"8e86a13bb7ae5cca3aa419cc","field":"drug.partd_spending","entity":"drug:abatacept|orencia"},{"fact_id":"5eb48f1997d11fe7eb6308d0","field":"drug.partd_spending","entity":"drug:abatacept|orencia"},{"fact_id":"b41816f7880aee8fc1185d0a","field":"drug.partd_spending","entity":"drug:abatacept|orencia"},{"fact_id":"ca18afa6139dbcb5379accb9","field":"drug.biologic_status","entity":"application:BLA125118"},{"fact_id":"c02b84ace98cd9ef34ba4dcc","field":"drug.asp_price","entity":"hcpcs:J0129"},{"fact_id":"127d42a4bf03c4d2853291e8","field":"drug.orphan_designation","entity":"drug:abatacept"},{"fact_id":"3d11d003acd0a62dd361cbe4","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003218713:MN"},{"fact_id":"540c6a76bd006c4ff049eda9","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003218851:NV"},{"fact_id":"92591658ecfd86a0e424b6ce","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003218851:UT"},{"fact_id":"b23c36971ee7cd3f65c70ed1","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003218713:KY"},{"fact_id":"ffb2d1e323a964944cfe3056","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003218713:WV"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"generic_entry:BLA125118","reason":"no generic-entry fact for this application: no patent or exclusivity is listed for it in the Orange Book edition read, so no date is stated"},{"code":"NO_DATA","field":"generic_entry","reason":"no application of this drug has a generic-entry fact; no date is stated"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"AMBIGUOUS","field":"spending","reason":"2 brand and generic name pairs match; the series shown is the one with the newest year and the largest spending"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}